Access cutting-edge prostate cancer treatment through this phase 1/2 clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this San Francisco location
Preparing your pre-screening questions…
Access prostate cancer specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prostate cancer treatment provided free
Check if you qualify for this prostate cancer clinical trial in San Francisco, CA
No-Cost Study Care
Local to San Francisco
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patients with advanced cancers that has spread to nearby tissue or lymph nodes (advanced). Granzyme B (GrB) is a biomarker produced by immune cells in response to immunotherapy, which may highlight tumors that are more likely to respond to treatment. The study population is focused on genitourinary (GU) malignancies, including renal cell and urothelial cancer, two tumor types with high mutational burden and tumor infiltrating lymphocytes compared to other tumor types, and have a predictable response rate at the population level to immune checkpoint inhibitors. The information gained from this trial may allow researchers to develop future trials where 64Cu-GRIP B PET may serve as a biomarker to monitor early response to immunomodulatory therapies which are used to stimulate or suppress the immune system and may help the body fight cancer.
Sponsor: Rahul Aggarwal
Yes, this clinical trial (NCT05888532) has an active research site in San Francisco, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for prostate cancer treatment options in San Francisco, CA, this clinical trial (NCT05888532) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all prostate cancer clinical trials near you to find additional studies recruiting in your area.
See all prostate cancer clinical trials recruiting in San Francisco — not just this study.
Browse Prostate Cancer Trials in San Francisco →